As of the most recent check, shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) have increased by 24.95% during pre-market activity, to $22.30. Positive clinical trial results that indicate possible improvements in the treatment of thyroid eye disease (TED) are the main driver of the notable increase in VRDN stock.
Revolutionary THRIVE-2 Phase 3 Findings
The THRIVE-2 phase 3 clinical trial’s positive topline findings were recently released by Viridian (VRDN). In patients with chronic TED, this trial assessed the effects of veligrotug (veli), an intravenous anti-insulin-like growth factor-1 receptor (IGF-1R) antibody.
Proptosis (eye bulging) and diplopia (double vision) are common symptoms of TED, a crippling inflammatory disease characterized by inflammation and tissue destruction around the eyes. The THRIVE-2 trial, encompassing the largest and most diverse chronic TED patient group studied globally, demonstrated robust efficacy and safety outcomes.
Remarkably, patients exhibited significant improvements after just five infusions of veli. These results align with data from the earlier THRIVE trial, underscoring veli’s potential as a treatment-of-choice for both active and chronic TED.
Impactful Outcomes for Patients
The trial’s findings showed statistically significant improvements in key areas that matter most to patients. These include reductions in proptosis, resolution of diplopia, and enhancements in Clinical Activity Scores (CAS).
Notably, veligrotug is the first treatment to achieve a diplopia response and resolution rate in a global chronic TED phase 3 study. With a shorter dosing regimen and a favorable safety profile, veli is poised to address critical unmet needs in the TED therapeutic landscape.
Path to Market Leadership
Viridian has initiated Biologics License Application (BLA) preparation for veligrotug. If approved, the drug will offer a differentiated commercial profile, potentially becoming the only therapy with labeling data for chronic TED patients.
Looking ahead, Viridian anticipates positive topline results from its subcutaneous VRDN-003 program by mid-2026, paving the way for a BLA submission in late 2026. With the success of THRIVE and THRIVE-2, Viridian’s veligrotug is on track to revolutionize TED treatment, improving quality of life for patients worldwide.
